OncoTricks

Hepatic artery infusion pump, Nov 3, 2026

The pump: what it does, what it costs

A man with colorectal cancer had his liver metastases resected last month. He now has a metal disc the size of a hockey puck under the skin of his abdomen, and comes to clinic for a "pump fill". What is in it, and what do you check before it is filled?

If you remember one thingLiver tumors live on the hepatic artery. The pump puts floxuridine straight into that artery, and the liver removes almost all of it before it reaches the rest of the body. The price is paid by the bile ducts, so the liver tests at every fill set the dose.

Concepts first

HAI
Hepatic artery infusion: chemotherapy given into the artery of the liver, here through a pump implanted at surgery.
The pump
A sealed reservoir under the skin. Its catheter sits in the gastroduodenal artery (a branch of the common hepatic artery) with the tip at the junction, so the drug flows into the hepatic artery. Gas-driven, fixed rate; no battery, no programming.
Floxuridine
Also called FUDR: a fluoropyrimidine, the family of fluorouracil (5-FU), with a short half-life that the liver extracts on its first pass. That is why it, not 5-FU, goes in the pump.
Perfusion scan
Radioactive albumin injected through the pump before the first dose, to prove the drug reaches the whole liver and not the stomach or duodenum.
Biliary sclerosis
Scarring and narrowing of the bile ducts caused by floxuridine. The bile ducts depend only on the artery, so they get the full dose.
WHERE THE DRUG GOESPump under the skincatheter in the gastroduodenal arteryHepatic artery+ floxuridinePortal veinno drugTumorfed by thearteryNormal liverfed mostly by the portal veinbile ducts: artery onlyLiver removes the floxuridine on first passlittle reaches the rest of the body

Why the artery.Tumor concentration up to 400 times that of systemic infusion, per the device maker; near-complete hepatic extraction keeps the rest of the body almost untouched (Lidsky 2023).

One cycle, 4 weeks

ONE 28-DAY CYCLEDays 1 to 14floxuridine + dexamethasoneDays 15 to 28heparin + salineFill: day 1Empty and refill: day 15Systemic chemotherapy on day 1 and day 15Liver tests before every fill, every 2 weeks

The Memorial Sloan Kettering (MSK) recipe, as written in their trials.Floxuridine 0.12 mg/kg/day and dexamethasone 1 mg/day, with heparin and saline, given for 14 days. Because the pump runs at a fixed rate, the amount loaded is scaled by the pump volume divided by its measured flow rate. On day 15 the pump is emptied and refilled with heparin and saline. Systemic chemotherapy goes in on days 1 and 15. Treatment starts at least 2 weeks after surgery (D'Angelica 2015). Each program sets its own starting dose; the liver tests then adjust it.

Why dexamethasone is in the pump

A randomized answer from 1992.In 50 patients, floxuridine with hepatic arterial dexamethasone versus floxuridine alone: a bilirubin rise of 200% or more in 9% versus 30% (P = 0.07), and response in 71% versus 40% (P = 0.03). Small trial, but the steroid stayed in the pump ever since (Kemeny 1992).

What it costs

most important

Bile ducts

6% at 5 years

Biliary sclerosis needing a stent or drain, 2239 patients at MSK. Rises with each cycle and with cumulative dose.

misperfusion

Stomach and duodenum

Ulcer, gastritis

If drug leaks into a branch artery. The perfusion scan before the first dose is meant to prevent it.

surgery and device

Pump and artery

17% severe

Pocket infection, pump or catheter dysfunction, dislodgement, arterial dissection or thrombosis: grade 3 (severe) in 17% of the PUMP trial.

The bile ducts pay.Stent-requiring sclerosis: 5.5% after adjuvant pump therapy (Ito 2012); 6% at 5 years in 2239 patients (Choubey 2026). Bevacizumab with pump floxuridine raised biliary toxicity enough to be dropped from an MSK trial (D'Angelica 2015).

At every floxuridine fill (day 1)

1. Jaundice, or bilirubin rising?
yes
Do not fill with floxuridineFill with heparin and saline. Image the bile ducts with magnetic resonance (MRCP); a stricture needs a stent. Rule out tumor progression.
no
2. Liver enzymes (AST, alkaline phosphatase) or bilirubin above the reference?Reference: the value on the day floxuridine was last given.
yes
Reduce or hold floxuridinePer your program's dose table. Early action is how strictures are prevented.
no
3. Epigastric pain, nausea, or bleeding?
yes
Do not fill with floxuridineSuspect drug reaching the stomach or duodenum. Heparin and saline; endoscopy and a repeat perfusion scan; resume only when perfusion is confined to the liver. Keep on a proton pump inhibitor.
no
Fill: floxuridine, dexamethasone, heparinCurrent dose, by today's weight and this pump's flow rate. First, the returned volume must match the expected one (fast pump or blocked catheter). Drug goes into the central reservoir only, never the bolus side port.
Living with a pump

Gas drives the pump, so heat and altitude speed it up.No heating pads, saunas or long hot tubs over the pump; tell the team before trips above 1,000 feet or flights in unpressurized planes; no scuba or contact sports. It sets off metal detectors, not body scanners: carry the device card (Mayo Clinic patient guide).

Memory hooks

Tap a card to flip it.

Check yourself

Question 1Why floxuridine in the pump and not 5-FU?

Floxuridine is almost completely extracted by the liver on its first pass and has a short half-life: high dose to the tumor, little to the rest of the body.

Question 2Fill day: bilirubin 3.1, was 0.8 two weeks ago. What goes in the pump?

Heparin and saline, no floxuridine. Image the bile ducts; a stricture needs a stent. Look for tumor progression too.

Question 3A patient on pump therapy has new epigastric pain and a duodenal ulcer. Why?

Drug reaching the stomach or duodenum through a branch artery. Hold floxuridine (heparin and saline), endoscopy, repeat the perfusion scan, proton pump inhibitor.

Sources

Retrieved from PubMed, the device maker and patient education pages, read on Nov 3, 2026.

  1. D'Angelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg 2015;261:353-360. doi:10.1097/SLA.0000000000000614
  2. Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992;69:327-334. doi:10.1002/1097-0142(19920115)69:2<327::aid-cncr2820690209>3.0.co;2-u
  3. Ito K, Ito H, Kemeny NE, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol 2012;19:1609-1617. doi:10.1245/s10434-011-2102-8
  4. Choubey AP, Seier K, Schleimer L, et al. Hepatic artery infusion pump chemotherapy associated biliary sclerosis after treatment for colorectal cancer liver metastasis. Ann Surg Oncol 2026;33:5990-6000. doi:10.1245/s10434-026-19505-4
  5. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-1403. doi:10.1200/JCO.2005.03.8166
  6. Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2020;6:60-67. doi:10.1001/jamaoncol.2019.3718
  7. Lidsky ME, Cercek A, Maithel SK, Kemeny N, D'Angelica MI. Hepatic arterial infusion pump chemotherapy: is it ready for prime time in the United States? ASCO Post, April 13, 2023.
  8. Boston Scientific. Intera 3000 hepatic artery infusion pump, product page. bostonscientific.com, accessed Nov 3, 2026.
  9. Mayo Clinic Staff. Hepatic artery infusion pump (HAIP) chemotherapy. Tests and procedures, mayoclinic.org, May 20, 2025.